A Randomized, Double-Blind, Placebo-Controlled Study of Flexible Doses of Levomilnacipran ER (40–120 Mg/Day) in Patients With Major Depressive Disorder
Journal of Drug Assessment
doi 10.3109/21556660.2014.884505
Full Text
Open PDFAbstract
Available in full text
Date
January 16, 2014
Authors
Publisher
Informa UK Limited